Methodological Issues in Antifungal Susceptibility Testing of Malassezia Pachydermatis
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Antibiotic Susceptibility of Bacterial Strains Causing Asymptomatic Bacteriuria in Pregnancy: a Cross- Sectional Study in Harare, Zimbabwe
MOJ Immunology Antibiotic Susceptibility of Bacterial Strains causing Asymptomatic Bacteriuria in Pregnancy: A Cross- Sectional Study in Harare, Zimbabwe Abstract Research Article Background and objective antibiotic susceptibility pattern: Effective among treatmentisolated bacterial of asymptomatic species among bacteriuria pregnant in Volume 6 Issue 1 - 2018 pregnancy requires susceptible drugs. The aim of this study was to determine womenMaterials with and asymptomatic Methods bacteriuria. : This study was conducted at 4 selected primary health 1Department of Nursing Science, University of Zimbabwe, care facilities in Harare, including pregnant women registering for antenatal Zimbabwe care at gestation between 6 and 22 weeks and without urinary tract infection 2Department of Medical Microbiology, University of Zimbabwe, symptoms. Asymptomatic bacteriuria was diagnosed by culture test of all Zimbabwe 3 midstream urine samples following screening by Griess nitrate test. Susceptibility Department of Obstetrics and Gynaecology, University of Zimbabwe, Zimbabwe test was done for all positive 24 hour old culture using the disk diffusion test. The resistant and intermediate. 4Institute of Clinical Medicine, University of Oslo, Norway minimum inhibitory concentration was measured and categorized as susceptible, Results *Corresponding author: : Tested antibiotics included gentamycin (88.2%), ceftriaxone (70.6%), Department of Nursing Science,Judith Mazoe Musona Street, Rukweza, PO Box nitrofurantoin (76.5%), ciprofloxacin (82.4%), ampicillin (67.6%) and norfloxacin University of Zimbabwe, College of Health Sciences, (61.8%). Prevalence of asymptomatic bacteriuria was 14.2% (95% CI, 10.28% to 19.22%). Coagulase negative staphylococcus was the most popular (29.4%) A198, Harare, Zimbabwe, Tel: 00263773917910; Email: bacteria followed by Escherichia coli (23.5%). Gentamycin (83.3%), ciprofloxacin Received: | Published: (75%) and ceftriaxone (70.8) overally had the highest sensitivity. -
Research Article Integrating Bacterial Identification and Susceptibility
Hindawi BioMed Research International Volume 2019, Article ID 8041746, 6 pages https://doi.org/10.1155/2019/8041746 Research Article Integrating Bacterial Identification and Susceptibility Testing: A Simple and Rapid Approach to Reduce the Turnaround Time in the Management of Blood Cultures Dariane C. Pereira1 and Luciano Z. Goldani 2 1Microbiology Unit, Laboratory Diagnosis Service, Hospital de Cl´ınicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil 2InfectiousDiseases Unit, Hospital de Cl´ınicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil Correspondence should be addressed to Luciano Z. Goldani; [email protected] Received 1 June 2019; Revised 15 August 2019; Accepted 16 September 2019; Published 3 October 2019 Academic Editor: Jiangke Yang Copyright © 2019 Dariane C. Pereira and Luciano Z. Goldani. -is is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. We evaluated a rapid bacterial identification (rID) and a rapid antimicrobial susceptibility testing by disk diffusion (rAST) from positive blood culture to overcome the limitations of the conventional methods and reduce the turnaround time in bloodstream infection diagnostics. -e study included hemocultures flagged as positive by bacT/ALERT , identification by MALDI-TOF MS, and rAST. -e results were compared to identification and antimicrobial susceptibility testing (AST)® results by current standard methods, after 24 h incubation. For rAST categorical agreement (CA), very major errors (VME), major errors (ME), and minor errors (mE) were calculated. A total of 524 bacterial samples isolated from blood cultures were obtained, including 246 Gram-negative (GN) and 278 Gram-positive (GP) aerobes. -
Central Asian and European Surveillance of Antimicrobial Resistance
Central Asian and European Surveillance of Antimicrobial Resistance CAESAR Manual Version 3.0 2019 Central Asian and European Surveillance of Antimicrobial Resistance CAESAR Manual Version 3, 2019 Abstract This manual is an update of the first edition published in 2015 and describes the objectives, methods and organization of the Central Asian and European Surveillance of Antimicrobial Resistance (CAESAR) network. It details steps involved for a country or area wanting to enrol in CAESAR, as well as steps involved in routine data collection for antimicrobial resistance (AMR) surveillance. It contains the protocols and AMR case definitions used by the network. Key updates involve the addition of Salmonella species to the list of pathogens under surveillance, as well as updates related to the European Committee on Antimicrobial Susceptibility Testing categories. CAESAR continues to coordinate closely with the European Antimicrobial Resistance Surveillance Network (EARS-Net) and strives for compatibility and comparability with EARS-NET, as well as the Global AMR Surveillance System coordinated by WHO headquarters. Keywords DRUG RESISTANCE, MICROBIAL ANTI-INFECTIVE AGENTS INFECTION CONTROL POPULATION SURVEILLANCE DATA COLLECTION Address requests about publications of the WHO Regional Office for Europe to: Publications WHO Regional Office for Europe UN City, Marmorvej 51 DK-2100 Copenhagen Ø, Denmark Alternatively, complete an online request form for documentation, health information, or for permission to quote or translate, on the Regional Office website (http://www.euro.who.int/pubrequest). © World Health Organization 2019 All rights reserved. The Regional Office for Europe of the World Health Organization welcomes requests for permission to reproduce or translate its publications, in part or in full. -
(Schizotrypanum) Cruzi in Dog Hosts Paulo Marcos Da Matta Guedes,1 Julio A
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Nov. 2004, p. 4286–4292 Vol. 48, No. 11 0066-4804/04/$08.00ϩ0 DOI: 10.1128/AAC.48.11.4286–4292.2004 Copyright © 2004, American Society for Microbiology. All Rights Reserved. Activity of the New Triazole Derivative Albaconazole against Trypanosoma (Schizotrypanum) cruzi in Dog Hosts Paulo Marcos da Matta Guedes,1 Julio A. Urbina,2 Marta de Lana,3 Luis C. C. Afonso,1 Vanja M. Veloso,1 Washington L. Tafuri,1 George L. L. Machado-Coelho,4 Egler Chiari,5 and Maria Terezinha Bahia1* Departamento de Cieˆncias Biolo´gicas,1 Departamento de Ana´lises Clínicas,3 and Departamento de Farma´cia,4 Universidade Federal de Ouro Preto, Ouro Preto, and Departamento de Parasitologia, Universidade Federal de Minas Gerais, Belo Horizonte,5 Minas Gerais, Brazil, and Centro de Biofísica y Bioquímica, Instituto Venezolano de Investigaciones Científicas, Caracas, Venezuela2 Received 25 March 2004/Returned for modification 8 June 2004/Accepted 20 July 2004 Albaconazole is an experimental triazole derivative with potent and broad-spectrum antifungal activity and a remarkably long half-life in dogs, monkeys, and humans. In the present work, we investigated the in vivo activity of this compound against two strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi, the causative agent of Chagas’ disease, using dogs as hosts. The T. cruzi strains used in the study were previously characterized (murine model) as susceptible (strain Berenice-78) and partially resistant (strain Y) to the drugs currently in clinical use, nifurtimox and benznidazole. Our results demonstrated that albaconazole is very effective in suppressing the proliferation of the parasite and preventing the death of infected animals. -
(IQC) Antimicrobial Susceptibility Tests Using Disk Diffusion
Internal Quality Control (IQC) Antimicrobial Susceptibility Tests Using Disk Diffusion National AMR Surveillance Network, NCDC National Programme on Containment of Antimicrobial Resistance National Centre for Disease Control, New Delhi April 2019 CONTENTS I. Scope .......................................................................................................................................................... 2 II. Selection of Strains for Quality Control ..................................................................................................... 2 III. Maintenance and Testing of QC Strains..................................................................................................... 3 Figure 1: Flow Chart: Maintenance of QC strains in a bacteriology lab......................................................... 4 IV. Quality Control (QC) Results—Documentation - Zone Diameter ............................................................. 5 V. QC Conversion Plan ................................................................................................................................... 5 1. The 20- or 30-Day Plan .......................................................................................................................... 5 2. The 15-Replicate (3× 5 Day) Plan ......................................................................................................... 5 3. Implementing Weekly Quality Control Testing ..................................................................................... 6 4. -
PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. -
WO 2014/195872 Al 11 December 2014 (11.12.2014) P O P C T
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/195872 Al 11 December 2014 (11.12.2014) P O P C T (51) International Patent Classification: (74) Agents: CHOTIA, Meenakshi et al; K&S Partners | Intel A 25/12 (2006.01) A61K 8/11 (2006.01) lectual Property Attorneys, 4121/B, 6th Cross, 19A Main, A 25/34 (2006.01) A61K 8/49 (2006.01) HAL II Stage (Extension), Bangalore 560038 (IN). A01N 37/06 (2006.01) A61Q 5/00 (2006.01) (81) Designated States (unless otherwise indicated, for every A O 43/12 (2006.01) A61K 31/44 (2006.01) kind of national protection available): AE, AG, AL, AM, AO 43/40 (2006.01) A61Q 19/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A01N 57/12 (2006.01) A61K 9/00 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, AOm 59/16 (2006.01) A61K 31/496 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, PCT/IB20 14/06 1925 KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (22) International Filing Date: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 3 June 2014 (03.06.2014) SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (25) Filing Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. -
A Ketoconazole Susceptibility Test for Malassezia Pachydermatis Using Modified Leeming–Notman Agar
Journal of Fungi Article A Ketoconazole Susceptibility Test for Malassezia pachydermatis Using Modified Leeming–Notman Agar Bo-Young Hsieh 1,2, Wei-Hsun Chao 3, Yi-Jing Xue 2 and Jyh-Mirn Lai 2,* 1 Lugu Township Administration, Nanto County 55844, Taiwan; [email protected] 2 College of Veterinary Medicine, National Chiayi University, No. 580, XinMin Rd., Chiayi City 60054, Taiwan; [email protected] 3 Department of Hospitality Management, WuFung University, Chiayi City 60054, Taiwan; [email protected] * Correspondence: [email protected]; Tel.: +886-5-2732920; Fax: +886-5-2732917 Received: 18 September 2018; Accepted: 14 November 2018; Published: 16 November 2018 Abstract: The aim of this study was to establish a ketoconazole susceptibility test for Malassezia pachydermatis using modified Leeming–Notman agar (mLNA). The susceptibilities of 33 M. pachydermatis isolates obtained by modified CLSI M27-A3 method were compared with the results by disk diffusion method, which used different concentrations of ketoconazole on 6 mm diameter paper disks. Results showed that 93.9% (31/33) of the minimum inhibitory concentration (MIC) values obtained from both methods were similar (consistent with two methods within 2 dilutions). M. pachydermatis BCRC 21676 and Candida parapsilosis ATCC 22019 were used to verify the results obtained from the disk diffusion and modified CLSI M27-A3 tests, and they were found to be consistent. Therefore, the current study concludes that this new novel test—using different concentrations of reagents on cartridge disks to detect MIC values against ketoconazole—can be a cost-effective, time-efficient, and less technically demanding alternative to existing methods. -
WO 2015/134796 Al 11 September 2015 (11.09.2015) P O P C T
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/134796 Al 11 September 2015 (11.09.2015) P O P C T (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 9/14 (2006.01) A61K 47/10 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A61K 9/16 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, PCT/US20 15/0 19042 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (22) International Filing Date: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 5 March 2015 (05.03.2015) SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 61/948,173 5 March 2014 (05.03.2014) US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, 14/307,138 17 June 2014 (17.06.2014) US TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (71) Applicant: PROFESSIONAL COMPOUNDING CEN¬ LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, TERS OF AMERICA [US/US]; 9901 South Wilcrest SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, Drive, Houston, TX 77099 (US). -
Rapid Identification and Antimicrobial Susceptibility Testing of Positive
Rapid identification and antimicrobial susceptibility testing of positive blood cultures using MALDI-TOF MS and a modification of the standardised disc diffusion test: a pilot study. Item Type Article Authors Fitzgerald, C;Stapleton, P;Phelan, E;Mulhare, P;Carey, B;Hickey, M;Lynch, B;Doyle, M Citation Rapid identification and antimicrobial susceptibility testing of positive blood cultures using MALDI-TOF MS and a modification of the standardised disc diffusion test: a pilot study. 2016 J. Clin. Pathol. DOI 10.1136/jclinpath-2015-203436 Publisher BMJ Journal Journal of clinical pathology Rights Archived with thanks to Journal of clinical pathology Download date 26/09/2021 22:03:45 Link to Item http://hdl.handle.net/10147/620889 Find this and similar works at - http://www.lenus.ie/hse Rapid Identification and Antimicrobial Susceptibility testing of Positive Blood Cultures using MALDI-TOF MS and a modification of the standardized disk diffusion test - a pilot study. Fitzgerald C1, Stapleton P1, Phelan E1 , Mulhare P1, Carey B1, Hickey M1, Lynch B1, Doyle M1. 1Microbiology Laboratory, University Hospital Waterford, Dunmore road, Waterford, Ireland Corresponding author: [email protected] Telephone: 00353-51-842488 Fax: 00353-51-848566 1 Keywords: blood culture, MALDI-TOF MS, rapid identification, rapid antimicrobial susceptibility testing, disk diffusion, clinical impact Word count: 3,000 Abstract Aims In an era when clinical microbiology laboratories are under increasing financial pressure, there is a need for inexpensive, yet effective, rapid microbiology tests. The aim of this study was to evaluate a novel modification of standard methodology for the identification and antimicrobial susceptibility testing (AST) of pathogens in positive blood cultures, reducing the turnaround time of laboratory results by 24 hours Methods 277 positive blood cultures had a gram stain performed, were o subcultured and incubated at 37 C in a CO2 atmosphere for 4 to 6 hours. -
A Comparison of Clinical Efficacy Between a Basic Shampoo With
Original Article A Comparison of Clinical Efficacy between a Basic Shampoo with Herbal Extracts Containing Climbazole and Its Similar Sample Containing Piroctone Olamine in the Treatment of Dandruff and Seborrheic Dermatitis Hosein Rastegar, PhD1 Abstract Hamidreza Ahmadi Ashtiani, PhD Background: Dandruff especially with itching and inflammation is a Student2 common complaint among patients in the clinic and its treatment is Mohammad Baghaei, Pharm D3 much challenging. Chemical anti fungal substances used in Saeid Bokaei, PhD4 antidandruff shampoos are common treatments. The aim of this study 5 was to compare the clinical efficacy of two of these anti dandruff Amirhoushang Ehsani, MD substances, climbazole and piroctone olamine in the treatment of Pedram Noormohammadpour, MD5 dandruff and seborrheic dermatitis in shampoos with herbal extracts. 5 Sahar Azizahari, MD Methods: One hundred and twenty men with scalp dandruff of the Ramin Khanmohammad6 same severity, between 20-30 years old and in the same occupational condition in terms of sun exposure or environmental 1. Laboratory Research Centre of Food and pollution were selected and divided randomly into two 60-subject Drug, Ministry of Health and Medical groups. After each shampoo was applied 3 times a week for 5 Educations, Islamic Republic of Iran weeks one in group 1 and the other in group 2, patients were 2. Department of Clinical Biochemistry, assessed for existence of itching and redness of scalp and reduction School of Medical Science, Tarbiat-e- in dandruff and results were compared between two groups. Modarres University, Tehran, Iran and Biochemistry & Nutrition Department of Results: Itching and redness were completely cured in both groups Zanjan Medical University and Institute of after treatment. -
WO 2018/102407 Al 07 June 2018 (07.06.2018) W !P O PCT
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/102407 Al 07 June 2018 (07.06.2018) W !P O PCT (51) International Patent Classification: TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, C07K 7/60 (2006.01) G01N 33/53 (2006.01) EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, CI2Q 1/18 (2006.01) MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, (21) International Application Number: KM, ML, MR, NE, SN, TD, TG). PCT/US2017/063696 (22) International Filing Date: Published: 29 November 201 7 (29. 11.201 7) — with international search report (Art. 21(3)) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/427,507 29 November 2016 (29. 11.2016) US 62/484,696 12 April 2017 (12.04.2017) US 62/53 1,767 12 July 2017 (12.07.2017) US 62/541,474 04 August 2017 (04.08.2017) US 62/566,947 02 October 2017 (02.10.2017) US 62/578,877 30 October 2017 (30.10.2017) US (71) Applicant: CIDARA THERAPEUTICS, INC [US/US]; 63 10 Nancy Ridge Drive, Suite 101, San Diego, CA 92121 (US). (72) Inventors: BARTIZAL, Kenneth; 7520 Draper Avenue, Unit 5, La Jolla, CA 92037 (US). DARUWALA, Paul; 1141 Luneta Drive, Del Mar, CA 92014 (US). FORREST, Kevin; 13864 Boquita Drive, Del Mar, CA 92014 (US).